arrow
R

Roch Houot

INSERM
H指数:60
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis

二线阿西美单抗 ciloleucel 在不适合移植的大B细胞淋巴瘤中的最终分析

2026-09-230
OAAI
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Nutritional outcomes associated with enteral versus parenteral nutritional support during intensive induction chemotherapy for acute myeloid leukemia

在急性髓系白血病强化诱导化疗期间,经肠内与经肠外营养支持的营养结局比较

2026-08-180
PRE
Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study

CAR T细胞疗法期间复发/难治性弥漫大B细胞淋巴瘤的标准化FDG-PET解读:一项DESCAR-T研究

2026-07-250
PRE
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

Englumafusp alfa联合glofitamab治疗b 细胞非霍奇金淋巴瘤: 1期试验

2026-07-160
OAAI
Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study

原发纵隔大B细胞淋巴瘤中循环肿瘤DNA的 interim assessment:一项多中心LYSA研究

2026-04-160
OA
Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis

原发性纵隔B细胞淋巴瘤患者在CAR-T细胞疗法失败后的结局与治疗模式:一项DESCAR-T分析

2025-12-010
OAAI
Length of hospital stay and outcome in primary central nervous system lymphoma: a French retrospective multicentric study

住院时间及预后在原发性中枢神经系统淋巴瘤中的关系:一项法国回顾性多中心研究

2025-11-270
OAAI
Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3

Brexucabtagene autoleucel 用于 BTKi 初治的复发/难治性套细胞淋巴瘤:ZUMA-2 研究队列 3 的主要分析

Blood
IF23.1
2025-10-310
PRE
Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry

CAR T细胞疗法后侵袭性B细胞淋巴瘤的晚期复发:一项来自DESCAR-T登记研究的LYSA研究

2025-10-240
OAAI
Invasive Fungal Infections after CD19 CAR T-cell Therapy for B-Cell Lymphoma: a LYSA study from the DESCAR-T Registry

CD19 CAR T细胞疗法治疗B细胞淋巴瘤后的侵袭性真菌感染:一项来自DESCAR-T登记研究的LYSA研究

2025-10-160
OAAI
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR-T细胞疗法失败后套细胞淋巴瘤患者的结局:Descar-T研究(Lysa集团)

2025-10-030
OAAI
B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK

B CAR T细胞疗法在原发性中枢神经系统淋巴瘤中的应用:LOC网络的多中心回顾性研究

2025-10-010
OA
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study

从ide-cel早期复发后使用靶向BCMA的双特异性抗体治疗效果不佳:一项法国真实世界研究

2025-09-200
OAAI
Brentuximab Vedotin addition to Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphoma: a LYSA Phase II Study

Brentuximab Vedotin联合Gemcitabine治疗复发或难治性外周T细胞淋巴瘤:一项LYSA II期研究

2025-08-060
OAAI
TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

TRANSCAR:CD19 CAR T细胞疗法在复发/难治性转化型惰性淋巴瘤中的真实世界疗效

2025-05-050
OAAI
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

Glofitamab在难治性或复发性弥漫性大B细胞淋巴瘤中的应用:一项在CAR-T细胞疗法失败后的II期LYSA研究

2025-04-030
PRE